Athletes Foot icon large

Over 70% of patients suffering from Onychomycosis also suffer from chronic Tinea pedis (athlete’s foot). Both are a common contagious fungal infection of the skin/nail that causes scaling, flaking, and itch of affected areas. Globally, it affects about 15% of the worldwide population and affects one out of five adults.

BB2603 is a first in class, nanoformulation of the most effective antifungal agent currently on the market and designed to treat both Onychomycosis and Tinea pedis at the same time. This formulation greatly enhances the efficacy of the drug as well as improving skin and nail penetration. BB2603 will be delivered as a spray that can be used to treat the feet as a whole clearing fungal infection from skin and nails.

Onychomycosis (fungal nail infection, FNI) is a serious and highly contagious infection of the nail that affects a wide proportion of the population and is particularly common in the elderly.  Onychomycosis can be caused by infection by a number of dermatophytes, most notably Trichophyton rubrum, Trichophyton mentagrophytes, and Epidermophyton floccosum, with T rubrum being the most common cause worldwide. The same dermatophytes can cause Tinea pedis (TP, or Athlete’s foot, AF) an infection of the soles of the feet and the interdigital spaces.

Onychomycosis requires long term treatment with topical antifungal lacquers or oral medication. Topical lacquers generally require 12 months treatment with very poor cure rates (often less than 20%). Tinea pedis can currently be treated with topical or oral antifungals or a combination of both. Topical agents are used for 1-6 weeks, depending on manufacturers’ recommendations. However, recurrence of tinea pedis approaches 90% and is often due to a patient’s discontinuance of medication after symptoms abate.